Targeting the tumor microenvironment in cancer

Why hyaluronidase deserves a second look

Clifford J. Whatcott, Haiyong Han, Richard G Posner, Galen Hostetter, Daniel D. Von Hoff

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Increased extracellular matrix (ECM) deposition is a characteristic observed in many solid tumors. Increased levels of one ECM component-namely, hyaluronan (HA)-leads to reduced elasticity of tumor tissue and increased interstitial fluid pressure. Multiple initial reports showed that the addition of hyaluronidase (HYAL) to chemotherapeutic regimens could greatly improve efficacy. Unfortunately, the bovine HYAL used in those studies was limited therapeutically by immunologic responses to treatment. Newly developed recombinant human HYAL has recently been introduced into clinical trials. In this article, we describe the role of HA in cancer, methods of targeting HA, and clinical studies performed to date, and we propose that targeting HA could now be an effective treatment option for patients with many different types of solid tumors.

Original languageEnglish (US)
Pages (from-to)291-296
Number of pages6
JournalCancer Discovery
Volume1
Issue number4
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Hyaluronoglucosaminidase
Tumor Microenvironment
Hyaluronic Acid
Extracellular Matrix
Neoplasms
Extracellular Fluid
Elasticity
Clinical Trials
Pressure
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting the tumor microenvironment in cancer : Why hyaluronidase deserves a second look. / Whatcott, Clifford J.; Han, Haiyong; Posner, Richard G; Hostetter, Galen; Von Hoff, Daniel D.

In: Cancer Discovery, Vol. 1, No. 4, 09.2011, p. 291-296.

Research output: Contribution to journalArticle

Whatcott, Clifford J. ; Han, Haiyong ; Posner, Richard G ; Hostetter, Galen ; Von Hoff, Daniel D. / Targeting the tumor microenvironment in cancer : Why hyaluronidase deserves a second look. In: Cancer Discovery. 2011 ; Vol. 1, No. 4. pp. 291-296.
@article{ee7ba9d63407426182191d28cf95943e,
title = "Targeting the tumor microenvironment in cancer: Why hyaluronidase deserves a second look",
abstract = "Increased extracellular matrix (ECM) deposition is a characteristic observed in many solid tumors. Increased levels of one ECM component-namely, hyaluronan (HA)-leads to reduced elasticity of tumor tissue and increased interstitial fluid pressure. Multiple initial reports showed that the addition of hyaluronidase (HYAL) to chemotherapeutic regimens could greatly improve efficacy. Unfortunately, the bovine HYAL used in those studies was limited therapeutically by immunologic responses to treatment. Newly developed recombinant human HYAL has recently been introduced into clinical trials. In this article, we describe the role of HA in cancer, methods of targeting HA, and clinical studies performed to date, and we propose that targeting HA could now be an effective treatment option for patients with many different types of solid tumors.",
author = "Whatcott, {Clifford J.} and Haiyong Han and Posner, {Richard G} and Galen Hostetter and {Von Hoff}, {Daniel D.}",
year = "2011",
month = "9",
doi = "10.1158/2159-8290.CD-11-0136",
language = "English (US)",
volume = "1",
pages = "291--296",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Targeting the tumor microenvironment in cancer

T2 - Why hyaluronidase deserves a second look

AU - Whatcott, Clifford J.

AU - Han, Haiyong

AU - Posner, Richard G

AU - Hostetter, Galen

AU - Von Hoff, Daniel D.

PY - 2011/9

Y1 - 2011/9

N2 - Increased extracellular matrix (ECM) deposition is a characteristic observed in many solid tumors. Increased levels of one ECM component-namely, hyaluronan (HA)-leads to reduced elasticity of tumor tissue and increased interstitial fluid pressure. Multiple initial reports showed that the addition of hyaluronidase (HYAL) to chemotherapeutic regimens could greatly improve efficacy. Unfortunately, the bovine HYAL used in those studies was limited therapeutically by immunologic responses to treatment. Newly developed recombinant human HYAL has recently been introduced into clinical trials. In this article, we describe the role of HA in cancer, methods of targeting HA, and clinical studies performed to date, and we propose that targeting HA could now be an effective treatment option for patients with many different types of solid tumors.

AB - Increased extracellular matrix (ECM) deposition is a characteristic observed in many solid tumors. Increased levels of one ECM component-namely, hyaluronan (HA)-leads to reduced elasticity of tumor tissue and increased interstitial fluid pressure. Multiple initial reports showed that the addition of hyaluronidase (HYAL) to chemotherapeutic regimens could greatly improve efficacy. Unfortunately, the bovine HYAL used in those studies was limited therapeutically by immunologic responses to treatment. Newly developed recombinant human HYAL has recently been introduced into clinical trials. In this article, we describe the role of HA in cancer, methods of targeting HA, and clinical studies performed to date, and we propose that targeting HA could now be an effective treatment option for patients with many different types of solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=84859983619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859983619&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-11-0136

DO - 10.1158/2159-8290.CD-11-0136

M3 - Article

VL - 1

SP - 291

EP - 296

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 4

ER -